OCULAR THERAPEUTIX, INC Deferred Tax Liabilities, Gross
OCULAR THERAPEUTIX, INC (OCUL) had Deferred Tax Liabilities, Gross of $3.08 million as of 2025-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-05
- 2025-12-31: Deferred Tax Liabilities, Gross $3.08M.
- 2024-12-31: Deferred Tax Liabilities, Gross $3.63M.
- 2023-12-31: Deferred Tax Liabilities, Gross $10.84M.
- 2022-12-31: Deferred Tax Liabilities, Gross $3.96M.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $3.08M 10-K · filed 2026-02-05 |
| 2024-12-31 | $3.63M 10-K · filed 2026-02-05 |
| 2023-12-31 | $10.84M 10-K · filed 2025-03-03 |
| 2022-12-31 | $3.96M 10-K · filed 2024-03-11 |
| 2021-12-31 | $3.60M 10-K · filed 2023-03-06 |
| 2020-12-31 | $4.42M 10-K · filed 2022-02-28 |
| 2019-12-31 | $4.96M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |